Cannabis ETFs: Risks and Opportunities
Legalization sounds like an obvious tailwind, yet cannabis ETFs have been one of the worst-performing themes of the past several years. Here's why the story and the returns diverged.
Don't have time? Here's what you need to know:
- 1Despite expanding legalization, many cannabis ETFs are down 80%+ from their 2018-2019 peaks as oversupply crushed margins.
- 2U.S. federal illegality drives the sector: 280E taxes, banking limits, and reliance on swaps to hold U.S. operators.
- 3These funds spike on political headlines and retreat when reform stalls — timing the catalyst is a losing game for most.
- 4Cannabis is a speculative, satellite-only position; size it as money you are prepared to lose entirely.
The Story Versus the Scoreboard
Cannabis is the clearest example of why a compelling narrative is not the same as a good investment. The pitch is irresistible: a once-illegal industry going mainstream, expanding legalization, and a generational shift in attitudes. Yet cannabis ETFs have been among the worst-performing thematic funds since the sector's 2018-2019 peak, with many down more than 80% from their highs.
The disconnect comes from the business reality underneath the story. Legalization expanded supply faster than profitable demand, prices collapsed in mature markets, and most cannabis companies have struggled to turn a profit. A growing industry can still be a terrible place for shareholders when too much capital chases it and margins evaporate — which is precisely what happened here.
Important: A growing end-market does not guarantee profits for investors. Cannabis demand rose while share prices collapsed, because oversupply and competition destroyed margins.
The U.S. vs Canadian Split That Defines These Funds
The single most important thing to understand before buying a cannabis ETF is whether it holds U.S. or Canadian operators, because U.S. federal law shapes everything. Cannabis remains federally illegal in the United States, which keeps most U.S. multi-state operators off major exchanges and forces specialized funds to use derivatives or swaps to gain exposure to names like the ones tracked by MSOS.
Older funds such as MJ leaned heavily on Canadian licensed producers — Canopy Growth, Tilray, Aurora — which trade on U.S. exchanges but have been chronic money-losers amid a glutted Canadian market. The federal overhang also blocks U.S. operators from normal banking and saddles them with a punishing tax rule (Section 280E) that taxes them on gross profit. This is a sector where the legal structure, not just the product, drives returns.
| Fund focus | Holds | Key constraint |
|---|---|---|
| U.S. operators | Multi-state operators via swaps | Federally illegal; 280E tax; banking limits |
| Canadian producers | Licensed producers (exchange-listed) | Oversupply; chronic losses |
| Ancillary plays | Real estate, equipment, biotech | Diluted exposure to the theme |
The Catalyst Trap: Trading on Political Headlines
Cannabis funds tend to spike on political headlines — talk of federal rescheduling, banking reform (the SAFE Banking Act), or a new state legalizing — and then give it all back when the legislation stalls. Investors who buy on the headline are repeatedly whipsawed, because the catalysts have a long history of being announced, anticipated, and then delayed for years.
Even a genuine positive change, like moving cannabis from Schedule I to Schedule III, may help operators' tax bills without curing the underlying oversupply and profitability problems. Betting on the timing of political outcomes is one of the hardest games in investing, and cannabis funds are essentially a leveraged wager on Washington moving faster than it usually does.
Tip: If you are buying a sector purely because you expect a specific law to pass, you are making a political forecast, not an investment. Size it accordingly — tiny.
Want the full framework? This 2-hour ETF course teaches you exactly how to pick, buy, and hold profitable ETFs — from zero to confident investor. Under $15.
If You Still Want Exposure
Cannabis is a speculative, satellite-only position at most. If you choose to participate, decide first whether you want U.S. operator exposure (higher upside if federal reform comes, but structural headwinds today) or a broader basket, and read the prospectus to see how the fund actually obtains its exposure — swaps and derivatives carry their own costs and counterparty risk.
Keep the position small enough that an 80% drawdown — which has already happened once — would not derail your plan. For nearly every investor, the prudent answer is to keep the long-term core in broad, low-cost index funds and treat cannabis as money you are genuinely prepared to lose. There is no defensive case for this sector; it is pure speculation.
Frequently Asked Questions
Why have cannabis ETFs performed so badly?
Legalization expanded supply faster than profitable demand, prices collapsed in mature markets like Canada, and most cannabis companies have failed to turn a profit. Many cannabis funds are down more than 80% from their 2018-2019 peaks. It is a case study in how a growing industry can still destroy shareholder value when oversupply crushes margins.
What's the difference between U.S. and Canadian cannabis ETFs?
U.S.-focused funds (like the basket MSOS tracks) hold multi-state operators and must use swaps because cannabis is federally illegal, which also burdens those firms with banking limits and the punishing 280E tax. Older funds like MJ leaned on exchange-listed Canadian producers such as Canopy and Tilray, which have been chronic money-losers amid oversupply. The legal structure largely drives returns.
Could federal legalization make cannabis ETFs soar?
Possibly, but it is a political bet with a long history of delay. Reforms like rescheduling or banking access could help operators' tax and financing burdens, yet may not fix the underlying oversupply and profitability problems. Funds tend to spike on headlines and give it back when legislation stalls, so timing the catalyst is extremely difficult.
Further Reading
Free Tools
Alex Harrington
CFA Level II Candidate, Finance & Economics
Alex Harrington is an independent ETF researcher and personal finance writer with over 8 years of experience analyzing exchange-traded funds. A CFA Level II candidate with a background in economics, Alex has reviewed 800+ ETFs and helped thousands of beginners build their first investment portfolios through clear, jargon-free education.
This content is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Consult a licensed financial advisor before making investment decisions.